Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis

M A Stone; U Payne; C Pacheco-Tena; R D Inman

doi:10.1136/ard.2003.006916

Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis

M A Stone, U Payne, C Pacheco-Tena, R D Inman

Research output: Contribution to journal › Article › peer-review

41 Citations (SciVal)

Abstract

Objective: To identify clinical and immunological markers of response to treatment with infliximab in ankylosing spondylitis (AS). Methods: Baseline and sequential cytokine levels (IL1, TNFalpha, IFNgamma, TGFbeta and IL10) were examined after 52 weeks of infliximab treatment 5 mg/kg in 22 patients. Results: At week 52, 18 patients were responders and four non-responders according to ASAS group criteria. Clinical measures of disease activity between the two groups at baseline were similar, apart from a trend towards longer disease duration in non-responders (p = 0.08). Baseline CRP and TNFalpha levels were higher in responders than non-responders (p

Original language	English
Pages (from-to)	84-87
Number of pages	4
Journal	Annals of the Rheumatic Diseases
Volume	63
Issue number	1
DOIs	https://doi.org/10.1136/ard.2003.006916
Publication status	Published - 2004

Bibliographical note

ID number: ISI:000187808300018

Access to Document

10.1136/ard.2003.006916

Cite this

@article{6f98ddca047246a783c2bd8b35e1ace4,

title = "Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis",

abstract = "Objective: To identify clinical and immunological markers of response to treatment with infliximab in ankylosing spondylitis (AS). Methods: Baseline and sequential cytokine levels (IL1, TNFalpha, IFNgamma, TGFbeta and IL10) were examined after 52 weeks of infliximab treatment 5 mg/kg in 22 patients. Results: At week 52, 18 patients were responders and four non-responders according to ASAS group criteria. Clinical measures of disease activity between the two groups at baseline were similar, apart from a trend towards longer disease duration in non-responders (p = 0.08). Baseline CRP and TNFalpha levels were higher in responders than non-responders (p",

author = "Stone, {M A} and U Payne and C Pacheco-Tena and Inman, {R D}",

note = "ID number: ISI:000187808300018",

year = "2004",

doi = "10.1136/ard.2003.006916",

language = "English",

volume = "63",

pages = "84--87",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "1",

}

TY - JOUR

T1 - Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis

AU - Stone, M A

AU - Payne, U

AU - Pacheco-Tena, C

AU - Inman, R D

N1 - ID number: ISI:000187808300018

PY - 2004

Y1 - 2004

N2 - Objective: To identify clinical and immunological markers of response to treatment with infliximab in ankylosing spondylitis (AS). Methods: Baseline and sequential cytokine levels (IL1, TNFalpha, IFNgamma, TGFbeta and IL10) were examined after 52 weeks of infliximab treatment 5 mg/kg in 22 patients. Results: At week 52, 18 patients were responders and four non-responders according to ASAS group criteria. Clinical measures of disease activity between the two groups at baseline were similar, apart from a trend towards longer disease duration in non-responders (p = 0.08). Baseline CRP and TNFalpha levels were higher in responders than non-responders (p

AB - Objective: To identify clinical and immunological markers of response to treatment with infliximab in ankylosing spondylitis (AS). Methods: Baseline and sequential cytokine levels (IL1, TNFalpha, IFNgamma, TGFbeta and IL10) were examined after 52 weeks of infliximab treatment 5 mg/kg in 22 patients. Results: At week 52, 18 patients were responders and four non-responders according to ASAS group criteria. Clinical measures of disease activity between the two groups at baseline were similar, apart from a trend towards longer disease duration in non-responders (p = 0.08). Baseline CRP and TNFalpha levels were higher in responders than non-responders (p

U2 - 10.1136/ard.2003.006916

DO - 10.1136/ard.2003.006916

M3 - Article

SN - 0003-4967

VL - 63

SP - 84

EP - 87

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 1

ER -

Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this